Form 4: Evoke Pharma Director Todd C. Brady Acquires Stock Options
SEC Form 4 Filing
Director Todd C. Brady of Evoke Pharma Inc. reports acquisition of stock options exercisable for 5,833 shares of common stock.
Summary
- Todd C. Brady, a director of Evoke Pharma Inc., filed a Form 4 disclosing a transaction involving derivative securities.
- On January 28, 2025, Brady acquired stock options for 5,833 shares of Evoke Pharma's common stock at an exercise price of $4.45.
- The options vest in three equal annual installments starting from the vesting commencement date, contingent upon continued service to the company.
- Following the reported transaction, Brady directly owns options for 5,833 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of transaction: Acquisition of stock options. |
| 01/29/2025 | Date of signature on the Form 4 filing. |
| 01/27/2035 | Expiration date of the stock options. |
Keywords
Form 4, Evoke Pharma, Stock Options, Beneficial Ownership, Director, EVOK, Brady, Todd C. Brady
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.